TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens. Read Here.
top of page
Recent Posts
See AllJohn Green’s new book Everything is Tuberculosis is scheduled to be published in Spring 2025. The novel laces the experiences of Henry, a...
110
The SIILTIBCY test is now available worldwide through the STOP TB GDF for $1.50 per dose. This novel testing option provides an...
80
The WHO has released the 2024 Global Tuberculosis Report and it places TB as the leading infectious disease killer, surpassing COVID-19....
150
bottom of page
Comments